Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

591
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
591
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

844
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
844
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

966
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
966
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Measurement of Blood Pressure01:17

Measurement of Blood Pressure

1.4K
Assessing blood pressure is a standard procedure executed in virtually all medical environments. The method utilized today was established over a hundred years ago by an innovative Russian doctor, Dr. Nikolai Korotkoff. The soft ticking noise, known as Korotkoff sounds, heard while taking blood pressure readings results from turbulent blood flow within the vessels. The apparatus required for this procedure includes a sphygmomanometer, a blood pressure cuff attached to a gauge, and a...
1.4K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Impact of an In-House Resident Clinical Pharmacist On-Call Program on Resident Physician Training: A Cross-Sectional Survey.

Journal of the American College of Clinical Pharmacy : JACCP·2026
Same author

Emergency Department-Based Education and mHealth Empowerment Intervention for Hypertension: The TOUCHED Randomized Clinical Trial.

JAMA cardiology·2025
Same author

Current use of push-dose epinephrine: Survey and interview results from academic clinicians in emergency medicine.

Academic emergency medicine : official journal of the Society for Academic Emergency Medicine·2025
Same author

A call to duty: Addressing Chicago's new migrant population's healthcare needs.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2024
Same author

Stronger, longer, better opioid antagonists? Nalmefene is NOT a naloxone replacement.

The International journal on drug policy·2024
Same author

Hypoglycemic Events in the Emergency Department.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2022

Video Experimental Relacionado

Updated: Sep 8, 2025

Invasive Hemodynamic Monitoring of Aortic and Pulmonary Artery Hemodynamics in a Large Animal Model of ARDS
08:12

Invasive Hemodynamic Monitoring of Aortic and Pulmonary Artery Hemodynamics in a Large Animal Model of ARDS

Published on: November 26, 2018

10.2K

Una reevaluación retrospectiva de los efectos hemodinámicos del Labetalol

Mary Margaret Rinker1, Teresa Valadez1,2, Renee Petzel Gimbar1,2

  • 1Department of Pharmacy Practice, University of Illinois at Chicago, Retzky College of Pharmacy, Chicago, IL, USA.

Journal of pharmacy practice
|August 23, 2025
PubMed
Resumen
Este resumen es generado por máquina.

Labetalol por vía intravenosa

Palabras clave:
La controversiala hemodinámicael labetalolfarmacologíaPotencia

Más Videos Relacionados

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis
08:05

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis

Published on: May 19, 2021

3.7K
Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

19.5K

Videos de Experimentos Relacionados

Last Updated: Sep 8, 2025

Invasive Hemodynamic Monitoring of Aortic and Pulmonary Artery Hemodynamics in a Large Animal Model of ARDS
08:12

Invasive Hemodynamic Monitoring of Aortic and Pulmonary Artery Hemodynamics in a Large Animal Model of ARDS

Published on: November 26, 2018

10.2K
Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis
08:05

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis

Published on: May 19, 2021

3.7K
Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

19.5K

Área de la Ciencia:

  • Farmacología
  • Medicina cardiovascular
  • Farmacia clínica

Sus antecedentes:

  • Labetalol es un antagonista adrenérgico comúnmente utilizado para el control de la presión arterial.
  • Las referencias actuales de fármacos citan una relación de potencia alfa-beta de 1:7 para el labetalol intravenoso, lo que sugiere un efecto cardiotrópico predominantemente negativo.
  • Esta relación informada contrasta con las observaciones de la práctica clínica.

Objetivo del estudio:

  • Para describir los efectos hemodinámicos en el mundo real del labetalol intravenoso (IV).
  • Comparar los efectos hemodinámicos observados con los documentados en las referencias oficiales de medicamentos.
  • Investigar la relación de potencia clínica entre alfa y beta del labetalol intravenoso.

Principales métodos:

  • Estudio de cohorte retrospectivo y observacional.
  • Incluidos los pacientes que reciben labetalol intravenoso por accidente cerebrovascular isquémico agudo en el departamento de urgencias.
  • Potencia clínica relativa (PCR) calculada como cambio medio de la presión arterial sistólica (PAS) dividido por el cambio de la frecuencia cardíaca (RC) en la hora siguiente a la administración.

Principales resultados:

  • Se analizaron 42 pacientes; edad media de 66 años, 71% mujeres.
  • La dosis mediana de 10 mg de labetalol intravenoso dio como resultado un promedio de ΔSBP de -35 mmHg y ΔHR de -9 bpm.
  • La PCR alfa-beta observada fue de aproximadamente 7: 2, que difiere significativamente de la proporción de 1: 7 en las referencias.
  • Diez pacientes experimentaron una reducción excesiva de la presión arterial espinal; no se observó bradicardia o taquicardia refleja.

Conclusiones:

  • La observación clínica indica una relación de potencia alfa-beta de 7: 2 para el labetalol IV, lo que contradice las referencias oficiales (1: 7).
  • Los hallazgos sugieren una discrepancia entre la experiencia clínica real y la información existente sobre el medicamento.
  • Recomienda actualizar las referencias oficiales para orientar mejor el uso clínico del labetalol intravenoso.